Halozyme (HALO) Rated Buy on Strong Royalty Growth
Summary
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now. On April 13, TD Cowen reaffirmed its Buy rating and $96 pri...
Original reporting
Open original sourceAFBytes is a read-only aggregator. Use the original source for full context and complete reporting.